Jesús Castilla Catalán-rekin lankidetzan egindako argitalpenak (27)

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2007

  1. Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): Metodología y primeros resultados

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 1, pp. 23-31

  2. Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters

    Gaceta Sanitaria, Vol. 21, Núm. 1, pp. 76-83

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis

  2. Impact of chronic hepatitis C on HIV-1 disease progression

    HIV Clinical Trials, Vol. 5, Núm. 3, pp. 125-131

2003

  1. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: Differences by transmission category

    AIDS, Vol. 17, Núm. 3, pp. 353-359

2002

  1. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

    Sexually Transmitted Infections, Vol. 78, Núm. 4, pp. 255-260

  2. Management of chronic viral hepatitis in HIV-infected patients: Spanish consensus conference

    HIV Clinical Trials, Vol. 3, Núm. 2, pp. 99-114

2001

  1. Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays

    Journal of Medical Virology, Vol. 64, Núm. 3, pp. 217-222

1999

  1. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.

    AIDS (London, England)

1998

  1. Interrelación entre la duración de la infección por el virus de la inmunodeficiencia humana, la viremia plasmática y la cifra de linfocitos CD4+

    Medicina Clinica, Vol. 110, Núm. 14, pp. 529-531

  2. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients [3]

    Journal of Hepatology

  3. The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load

    Journal of Infection, Vol. 36, Núm. 3, pp. 307-311

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230

  2. Addition of lamivudine to the drug regimen in patients with advanced HIV disease on nucleoside therapy [4]

    European Journal of Clinical Microbiology and Infectious Diseases

  3. Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C [3]

    Journal of Infection

  4. Comparison of three different commercial methods for quantification of plasma HIV RNA in clinical specimens.

    Antiviral therapy

  5. Cuantificación de la viremia en pacientes infectados por el virus de la inmunodeficiencia humana con diferentes grados de inmunodepresión

    Revista Clinica Espanola, Vol. 197, Núm. 12, pp. 810-813

  6. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C

    American Journal of Gastroenterology, Vol. 92, Núm. 7, pp. 1130-1134

  7. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy [13]

    AIDS